Therapies for inherited retinal degeneration
Models for Therapy of Hereditary Retinal Degeneration
Using gene and cell therapies in dog models to create new treatments for people with inherited retinal diseases like retinitis pigmentosa and Best disease.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Pennsylvania NIH-funded |
| Lab location | 1 site (Philadelphia, United States) |
| Project ID | NIH-11251942 on NIH RePORTER |
What this research studies
This program studies naturally occurring dog models that have the same kinds of inherited retinal diseases people get, so researchers can see how the disease develops and test potential treatments. The team breeds and maintains specific canine strains and uses AAV-based gene delivery and cell-replacement approaches to try to slow or reverse retinal degeneration. Findings from these preclinical tests help decide which therapies are safe and promising enough to move toward human clinical trials. The work builds on earlier successes where dog studies guided development of human gene and cell therapies.
Who could benefit from this research
Good fit: People with inherited retinal diseases such as retinitis pigmentosa, Leber congenital amaurosis, cone-rod dystrophy, or Best macular dystrophy would be the eventual candidates for therapies developed through this work.
Not a fit: Patients with non-genetic retinal conditions (for example typical age-related macular degeneration), or those whose eyes are already end-stage with no remaining viable photoreceptors, are unlikely to benefit from these specific approaches.
Why it matters
Potential benefit: If successful, this work could lead to new gene or cell-based treatments that slow, stop, or partially restore vision loss from inherited retinal diseases.
How similar studies have performed: Related gene and cell therapy approaches have produced promising results in earlier dog-model work and in some early human trials, though many specific IRDs still lack effective treatments.
Where this research is happening
Philadelphia, United States
- University of Pennsylvania — Philadelphia, United States (Active)
Researchers
- Principal investigator: Beltran, William a. — University of Pennsylvania
- Study coordinator: Beltran, William a.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.